Medtech Start-Ups Innovate In Treating Advanced Skin Cancer
This article was originally published in Start Up
Nanotechnology, electroporation, and superficial radiotherapy are some of the tools device start-ups are deploying as alternatives to toxic drug regimens and surgery for treating skin cancer. We profile three emerging companies in this issue: OncoSec Medical, Sensus Healthcare, and Siva Therapeutics.
You may also be interested in...
Siva Therapeutics Inc. aims to destroy skin cancer cells from within by using its SivaRods, gold nanoparticles that combine with near-infrared light to create precisely targeted hyperthermia that destroys tumors with minimal collateral damage.
Sensus Healthcare LLC has developed an alternative to Mohs surgery for non-melanoma skin cancers. Its SRT-100 is a mobile, low-energy radiotherapy system designed specifically for the cost-effective, noninvasive treatment of NMSCs. Unlike radiotherapy technologies used for treating other cancers, including linear accelerators and electron beam therapy, the radiation does not travel through the body and destroy healthy tissue.
OncoSec Medical Inc. has developed electroporation-based technology for deadly Stage III and IV metastatic melanoma, and two rare but aggressive orphan skin cancer indications. Its ImmunoPulse platform delivers DNA IL-12 into electroporated cells, triggering each cell to produce and secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.